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Summary
Objectives: To elucidate the role of granzyme B in coronary artery disease (CAD)
in patients with chronic kidney disease (CKD). We hypothesized that granzyme B
plays an important role in the formation of coronary artery lesions in patients with
CKD.
Patients and methods: We studied 141 patients (116 men and 25 women; mean age,
64.2± 9.6 years) and 16 control subjects. Diagnosis of CAD was conﬁrmed by selec-
tive coronary angiography. CKD was deﬁned as a sustained decrease in the estimated
glomerular ﬁltration (eGFR) rate less than 60mL/min/1.73m2 over 3 months. We
assigned patients to three groups: CAD without CKD (CAD group, n = 46), CKD with-
out CAD (CKD group, n = 18), and CAD with CKD (CAD/CKD group, n = 77). Plasma
granzyme B was measured by enzyme-linked immunosorbent assay. Factors con-
tributing to the severity of CAD were analyzed by multiple regression analysis in
patients with CAD.
Results: Plasma levels of high-sensitivity CRP (hs-CRP) and granzyme B in the
CAD/CKD group were signiﬁcantly higher than in other groups. A signiﬁcant pos-
itive correlation was observed between plasma hs-CRP and granzyme B levels. A
signiﬁcant negative correlation was observed between eGFR and granzyme B lev-
els. Multiple regression analysis revealed that granzyme B and hs-CRP levels were
independent predicting variables of the number of stenoses in major coronary
arteries.
∗ Corresponding author. Tel.: +81 285 58 7344; fax: +81 285 44 5317.
E-mail address: yhojo@jichi.ac.jp (Y. Hojo).
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lts indicate that granzyme B might be a novel risk factor for
y atherosclerosis by inducing apoptosis of vascular tissues in
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Introduction
A number of epidemiological studies have reported
that chronic kidney disease (CKD) is an indepen-
dent risk factor for cardiovascular diseases [1—3].
Cardiovascular mortality is highest in patients with
end-stage renal disease; however, a signiﬁcant
increase in cardiovascular events has been observed
even among patients with mild renal insufﬁciency
[1]. It has also been reported that clinical out-
come of percutaneous coronary intervention is not
sufﬁcient enough in patients with end-stage renal
disease [2]. Although a number of reports have
demonstrated increased cardiovascular mortality in
CKD, the precise mechanisms of how CKD takes
part in the onset of cardiovascular diseases are still
not fully understood. It has been speculated that
hypertension, dyslipidemia, malnutrition, homo-
cysteine, oxidative stress, and inﬂammation are
involved in the progression of atherosclerosis in
patients with CKD [3—7]. Among humoral factors,
interleukins, tumor necrosis factors, and trans-
forming growth factors are possible candidates
to promote atherosclerotic processes in patients
with CKD by triggering endothelial dysfunction
[8—11].
Recently, we have reported that the production
of granzyme B from peripheral blood mononuclear
cells was increased in patients with acute coro-
nary syndrome [12]. Granzyme B is a member of
the serine protease family released from cytotoxic
lymphocytes and plays an important role in cellu-
lar apoptosis by activating intracellular caspases.
Granzyme B induces cell death by mechanisms
such as the activation of caspases, degradation of
structural proteins, and directing the proapoptotic
molecule Bid to the mitochondrial compartment
[13,14]. Chamberlain et al. have reported that
granzyme B might play important roles in the
progression of atherosclerosis in patients receiv-
ing heart transplant surgery via the induction of
endothelial apoptosis [15,16]. It is possible that
proapoptotic molecules are involved in the for-
mation of atherosclerosis in a group of patients
with immunological disorders [17]. Interestingly,
patients with chronic renal failure are reported to
have various immunological disorders that are sig-iﬁcant contributing factors for long-term survival
18—20].
High-sensitivity C-reactive protein (hs-CRP) is
seful to evaluate high-risk CKD patients with
oronary atherosclerosis, however non-speciﬁc ele-
ation might reduce the sensitivity and speciﬁcity
f this marker. We hypothesized that granzyme B
ight also be useful to detect coronary atheroscle-
osis in patients with CKD in addition to hs-CRP. We
ave measured the plasma levels of granzyme B in
atients with coronary artery disease (CAD) with or
ithout CKD to examine the role of granzyme B in
AD patients accompanied by CKD.
ubjects and methods
he Ethics Committee of Jichi Medical University
pproved the protocol of this study. All patients
nrolled in this study gave informed consent.
atients
onsecutive patients who underwent coronary
ngiography in Jichi Medical University Hospital
etween October 2006 and October 2007 were
ncluded in this study. We studied 141 patients (116
en and 25 women, aged 64.2± 9.6 years, rang-
ng from 38 to 81 years) who underwent coronary
ngiography in our hospital. ‘‘CAD’’ patients were
eﬁned as patients showing signiﬁcant coronary
tenosis diagnosed by selective coronary angiog-
aphy. ‘‘CKD’’ patients were deﬁned as patients
ho showed sustained proteinuria (over 2+ by
emi-quantiﬁcation method) for more than three
onths and/or an estimated glomerular ﬁltration
ate (eGFR) less than 60mL/min/1.73m2 according
o the US National Kidney Foundation [21]. Brieﬂy,
GFR was calculated using the simpliﬁed prediction
quation described below derived from the collab-eGFR (mL/min/1.73m2)
= 194 × creatinine−1.094
×age−0.287(×0.739 if female).
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We divided patients into three groups accord-
ng to the presence of CAD and CKD; CAD group
CAD patients without CKD, n = 46), CKD group (CKD
atients without CAD, n = 18), and CAD/CKD group
CAD patients with CKD, n = 77). The CKD group
ncluded 2 patients with valvular heart disease, 1
ortic aneurysm, 1 thoracic aneurysm, and 14 chest
ain patients without the evidence of coronary
therosclerosis or variant angina. Patients with-
ut CAD or CKD (n = 16, 10 men and 6 women,
ged 65.0± 8.2 years, ranging from 38 to 81 years)
ere also recruited to the study as a control
roup. All control subjects underwent coronary
ngiography because of chest pain. No signiﬁcant
oronary stenosis was observed in control sub-
ects.
We excluded patients with acute coronary
yndrome, acute inﬂammatory disease, acute
enal failure, hematological disorder, malignancy,
nd patients taking immunosuppressive medicine.
ypertension, diabetes mellitus, and dyslipidemia
ere diagnosed according to the criteria described
y Ninomiya et al. [23]. Hs-CRP was measured by
he latex nephelometry method described by Ledue
t al. [24].
easurement of plasma granzyme B levelshe concentration of granzyme B in plasma was
etermined using enzyme-linked immunosorbent
ssay kits according to the manufacturer’s instruc-
ions (Kamiya Biomedical Company, Seattle, WA,
SA). The lower limit of granzyme B detection was
g
t
t
t
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Table 1 Baseline characteristics of the three study groups
CAD group
n 46
Age (years old) 62.7± 9.9
Gender (male/female) 41/5
Hypertension 36 (78.3%)
Dyslipidemia 29 (63.0%)
Diabetes mellitus 20 (43.5%)
Smoking 25 (54.3%)
Family history of CAD 13 (28.3%)
Vessel diseasea 1/23/10/12
LVEF 65.7± 1.4%
History of OMI 6 (13.0%)
eGFR (mL/min/1.73 m2) 76.7± 13.2
hs-CRP (ng/mL) 2420± 763
CAD, coronary artery disease; CKD, chronic kidney disease; LVEF, lef
eGFR, estimated glomerular ﬁltration rate; hs-CRP, high-sensitivity
ʃ p < 0.001 versus CAD group.
¶ p < 0.01 versus CAD group.
‡ p < 0.001 compared with CAD group.
† p < 0.01 compared with CAD group (Kruskal—Wallis test).
a 0-/1-/2-/3-vessel disease and lesions including left main trunkrtery disease—–Clinical signiﬁcance in patients 411
.3 pg/mL. Intra-assay variation of the kit is 6.5%
nd inter-assay variation less than 10%.
tatistical analysis
ll values are expressed as the means± SEM unless
therwise indicated. The signiﬁcant difference in
roportion was examined by the chi-square test.
he signiﬁcance of differences among the three
roups was determined by one-way analysis of vari-
nce. If data did not follow Gaussian distribution,
he signiﬁcance of the three groups was deter-
ined by the Kruskal—Wallis test. The relationship
etween two variables was examined by calculating
earson’s correlation coefﬁcient and the corre-
ponding p values. Multiple regression analysis was
onducted with computer software (SPSS version
6.0, Chicago, IL, USA). Values of p < 0.05 were con-
idered signiﬁcant.
esults
aseline characteristics of subjects
able 1 shows the baseline characteristics of the
tudy subjects. As shown in Table 1, mean age,
ender, and the incidence of coronary risk fac-
ors were not signiﬁcantly different among the
hree groups. Left ventricular ejection fraction in
he CKD group and CAD/CKD groups was signiﬁ-
antly lower than in the CAD group. The hs-CRP in
.
CKD group CAD/CKD group
18 77
61.3± 12.4 65.7± 8.4
13/5 62/151
12 (66.7%) 68 (88.3%)
6 (33.3%) 41 (53.2%)
7 (38.9%) 41 (53.2%)
9 (50.0%) 41 (53.2%)
1 (0.06%) 18 (23.3%)
18/0/0/0 3/37/15/22
51.6± 3.7%ʃ 58.5± 1.6%¶
0 (0%) 17 (22.0%)
14.7± 12.5‡ 27.1± 21.1‡
2818± 1156 7294± 2193†
t ventricular ejection fraction; OMI, old myocardial infarction;
C-reactive protein.
.
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Figure 1 Levels of plasma granzyme B in study patients.
The Kruskal—Wallis test revealed that plasma levels
of granzyme B in CAD/CKD patients were signiﬁcantly
higher than those in control subjects, patients with CAD
Figure 2 Simple correlations between plasma granzyme
B levels and clinical parameters. Panel A: correlation
between plasma granzyme B and estimated glomelular
ﬁltration rate (eGFR). A signiﬁcant negative correla-
tion was found between these parameters (r =−0.33,
p < 0.001). Panel B: a signiﬁcant positive correlation
was found between plasma granzyme B levels and log-
t
l
M
of coronary artery disease
We examined the independent contributing fac-
tors for the severity of CAD in patients with CAD
Table 2 Predicting factors for plasma granzyme B
levels.
ˇ coefﬁcient p value
Age +0.031 0.693
Sex −0.130 0.113
Body mass index −0.038 0.640
Hypertension −0.012 0.884
Dyslipidemia −0.143 0.069
Diabetes mellitus +0.202 0.015
Current smoker −0.042 0.614
Family history +0.080 0.290or patients with CKD (control, 7.1± 1.0 pg/mL; CAD,
10.6± 2.8 pg/mL; CKD, 27.3± 3.3 pg/mL; CAD/CKD,
35.5± 8.1 pg/mL; p < 0.001). *p < 0.05, ‡p < 0.001. CAD,
coronary artery disease; CKD, chronic kidney disease.
the CAD/CKD group was signiﬁcantly higher than
that in CKD or CAD group. As shown in Figure
1, plasma granzyme B levels in the CAD/CKD
group were signiﬁcantly higher than in the control
group, CAD, or CKD group (control, 7.1± 1.0 pg/mL;
CAD, 10.6± 2.8 pg/mL; CKD, 27.3± 3.3 pg/mL;
CAD/CKD, 35.5± 8.1 pg/mL; p < 0.001).
Correlation between granzyme B and other
parameters
As shown in Figure 2A, there was a signiﬁcant nega-
tive correlation between plasma granzyme B levels
and eGFR (r =−0.33, p < 0.001). Similarly, a signif-
icant positive correlation was observed between
plasma granzyme B levels and creatinine levels
(r = +0.27, p = 0.001). There was a positive correla-
tion between plasma granzyme B levels and hs-CRP
with marginal signiﬁcance (r = +0.39, p = 0.07). As
shown in Figure 2B, a signiﬁcant positive correla-
tion was observed plasma granzyme B levels and
logarithmic (log)-transformed hs-CRP (r = +0.23,
p < 0.01). Next, we conducted multivariate regres-
sion analysis to examine the factors contributing to
plasma granzyme B levels. We set plasma granzyme
B levels as a responsible variable and age, sex, body
mass index, hypertension, dyslipidemia, diabetes
mellitus, current smoker, family history of CAD,
eGFR, and log-transformed hs-CRP as explanatory
variables. As shown in Table 2, diabetes mellitus
and eGFR were signiﬁcant factors contributing to
plasma granzyme B levels (F = 0.310, p = 0.002).ransformed high-sensitivity C-reactive protein (hs-CRP)
evels (r = +0.23, p < 0.01).
ultivariate regression analysis for severityeGFR −0.275 0.001
hs-CRP +0.108 0.176
eGFR, estimated glomerular ﬁltration rate; hs-CRP, high-
sensitivity C-reactive protein.
Plasma granzyme B as a predicting factor of coronary a
(CAD and CAD/CKD groups). The number of signif-
icant stenoses in the major coronary artery was
used as the responsible variable (zero-vessel dis-
ease, 0; one-vessel disease, 1; two-vessel disease,
2; three-vessel disease and lesions including left
main trunk, 3). We established threemodels to clar-
ify the predicting factor for the severity of CAD by
setting age, sex, body mass index, hypertension,
dyslipidemia, diabetes mellitus, current smoker,
family history of CAD, eGFR, log-transformed hs-
CRP level, and plasma granzyme B levels as
explanatory variables. Model 1 includes patients’
demographic data and plasma granzyme B levels.
Model 2 includes classic risk factors for atheroscle-
rosis as explanatory variables in addition to the
Model 1. Model 3 includes body mass index,
eGFR, and log-transformed hs-CRP as explana-
tory variables in addition to the Model 2. As
shown in Table 3, we found that the plasma
granzyme B level and hs-CRP were signiﬁcant
predicting factors for severity of CAD in all mod-
els.
Table 3 Predicting factors for severity of coronary
artery disease.
 coefﬁcient p value
Model 1: F = 346, p = 0.019
Age +0.093 0.300
Sex +0.041 0.645
Plasma granzyme B levels +0.258 0.004
Model 2: F = 2.02, p = 0.050
Age +0.108 0.240
Sex +0.040 0.682
Hypertension +0.022 0.810
Dyslipidemia −0.031 0.741
Diabetes mellitus +0.159 0.113
Current smoking +0.110 0.258
Family history of CAD −0.201 0.811
Plasma granzyme B levels +0.207 0.029
Model 3: F = 2.06, p = 0.029
Age +0.094 0.305
Sex +0.035 0.725
Body mass index −0.070 0.468
Hypertension +0.034 0.718
Dyslipidemia −0.006 0.948
Diabetes mellitus +0.135 0.179
Current smoking +0.117 0.228
Family history of CAD −0.017 0.851
eGFR +0.121 0.223
hs-CRP (log-transformed) +0.197 0.044
Plasma granzyme B levels +0.195 0.049
eGFR, estimated glomerular ﬁltration rate; hs-CRP, high-
sensitivity C-reactive protein; CAD, coronary artery disease.
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omparison of plasma granzyme B levels
etween patients with or without
emodialysis
ecause a signiﬁcant negative correlation was
bserved between plasma granzyme B levels and
GFR, we examined granzyme B levels in patients
ith end-stage renal disease. We compared plasma
ranzyme B levels in patients with or without
emodialysis (HD). We divided CAD/CKD patients
ccording to HD treatment; CAD/CKD with HD group
n = 33) and CAD/CKD without HD group (n = 44).
here were no signiﬁcant differences in terms of
ge, sex, and coronary risk factors between two
roups. Plasma granzyme B levels in the CAD/CKD
ith HD group were signiﬁcantly higher than in the
AD/CKD without HD group (67.4± 17.7 pg/mL ver-
us 12.2± 1.9 pg/mL, p < 0.001). We did not ﬁnd a
igniﬁcant difference in granzyme B levels in the
AD/CKD group without HD and CKD group without
D (12.2± 1.9 pg/mL versus 21.9± 3.8 pg/mL).
iscussion
he present study has shown that the plasma
ranzyme B level was elevated in CAD patients
ith CKD. Univariate analysis showed that plasma
ranzyme B is related to renal function and inﬂam-
ation. Multivariate regression analysis disclosed
hat diabetes mellitus and eGFR were signiﬁcant
actors for the elevation of plasma granzyme B lev-
ls. Interestingly, multivariate regression analysis
as revealed that the plasma granzyme B level is
signiﬁcant independent factor for the severity
f CAD together with hs-CRP. In addition, plasma
ranzyme B was markedly elevated in CAD patients
eceiving HD.
Elevation of circulating inﬂammatory cytokines,
ecreased anti-inﬂammatory cytokines, and acti-
ation of lymphocytes have been reported in
atients with chronic kidney disease [25—27].
e focused on the perforin/granzyme system in
AD patients with CKD because a previous report
as shown the activation of T lymphocytes in
atients with renal failure [25]. Normally, the
erforin/granzyme system induces apoptosis of
nfected cells and cancer cells. It is reported that
ranzyme B injures endothelial cells in patients
ith immunological dysregulation, such as recip-ents of allograft transplantation [28]. It has also
een reported that administration of a serine pro-
ease inhibitor attenuated atheromatous plaque
ormation in apoE-knockout mice [29] and vascular
njury after allograft transplantation [30]. Thus, it
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is possible that serine proteases play an important
role in atheromatous plaque formation in certain
group of patients.
We have observed that phorbol-12-myristate-13-
acetate, a protein kinase C activator, upregulated
the release of granzyme B from cultured peripheral
blood mononuclear cells; thus, a protein kinase C-
mediated mechanism is at least partially involved
in granzyme B expression [12]. It has been reported
that patients with diabetes mellitus are under the
condition of increased cellular protein kinase C
activity. Conversely, granzyme B might play an
important role in patients with diabetic angiopathy.
We found that plasma granzyme B and hs-CRP
were independent factors for the severity of CAD.
Our data also showed that decreased renal func-
tion is a factor in the elevation of plasma granzyme
B levels. Interestingly, eGFR was not a predicting
factor for the severity of CAD; thus, it is possible
that granzyme B is an important mediator to con-
nect renal dysfunction and coronary atherosclerosis
in patients with CKD.
CAD/CKD patients receiving hemodialysis
showed extremely high plasma granzyme B levels
and it is possible that cytotoxic lymphocytes
are activated in patients receiving hemodialysis.
This immunological disorder might be evoked
by direct contact of circulating blood cells with
the hemodialysis membrane. Proinﬂammatory
molecules that cannot be eliminated by hemodial-
ysis might also upregulate circulating granzyme B
levels in patients receiving HD.
In conclusion, we have demonstrated that
granzyme B is a novel risk factor for coronary
atherosclerosis in CKD patients, particularly in end-
stage renal disease. The plasma granzyme B level
could be a marker to detect high-risk patients
with cardiovascular complications in CKD patients
in addition to hs-CRP. Inhibition of granzyme B could
prevent coronary atherosclerosis in certain groups
of patients.
Study limitations
First, we calculated the eGFR value in patients
receiving HD. The serum creatinine level changes
drastically by HD. Thus eGFR in patients receiv-
ing HD might not be accurate. We have to take
into account this point in interpretation of data.
We could not measure plasma levels of intrinsic
granzyme B inhibitor, protease inhibitor 9 in our
study patients; therefore, we did not know plasma
granzyme B activity in our study patients. We have
tried to measure plasma granzyme B activity using a
ﬂuorescent or colorimetric substrate; however, we
could not obtain reproducible results in the present
[T. Ikemoto et al.
tudy. In addition, a prospective study with a large
opulation of patients should be performed to elu-
idate the clinical signiﬁcance of granzyme B in
uture cardiovascular events.
cknowledgment
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